title: Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
abstract: To investigate GVL effects, Balb/c mice (H-2d) received 5 x 10(5) A20 (B cell leukemia) or 1 x 10(6) WEHI-3 (myelomonocytic leukemia) cells. These cell lines lead to death after a median of 19 (WEHI-3) or 30 days (A20). A lethal dose of total body irradiation followed by syngeneic BMT resulted in significantly prolonged survival of leukemia-bearing animals. Transplantation of (C57 x Balb/c)F1 (H-2bxd) allogeneic, but GVH-non-reactive marrow grafts differentially influenced the relapse rates in the two leukemia models. Whereas allogeneic BMT reduced the relapse rates in A20-bearing mice, the leukemia-free survival was not improved in mice bearing the leukemia WEHI-3 compared with syngeneic BMT. Pre-treatment of allogeneic (C57 x Balb/c)F1 or syngeneic Balb/c marrow cells with 200 U/ml IL-2 for 24 h did not reduce relapse rates in animals inoculated with A20 leukemia cells compared with unmanipulated bone marrow. In contrast, IL-2 treatment of syngeneic or allogeneic GVH non-reactive donor marrow significantly decreased the relapse rate in mice inoculated with WEHI-3 leukemia cells. The NK cell-mediated lysis of cultured leukemia cells was determined in vitro using a conventional 56Cr-release assay. Our data revealed a strong correlation between the level of natural killer activity determined in vitro and GVL activity in vivo.
authors.affiliation: Institute for Immunology, University of Kiel, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Zeis
authors.forename: L
authors.initials: L
authors.lastname: Uharek
authors.forename: B
authors.initials: B
authors.lastname: Glass
authors.forename: T
authors.initials: T
authors.lastname: Gaska
authors.forename: W
authors.initials: W
authors.lastname: Gassmann
authors.forename: W
authors.initials: W
authors.lastname: Mueller-Ruchholtz
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D005260:Female; D006087:Graft vs Host Reaction / Q000276:immunology*; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology; D015448:Leukemia, B-Cell / Q000276:immunology / Q000628:therapy; D007942:Leukemia, Experimental / Q000276:immunology* / Q000628:therapy*; D015479:Leukemia, Myelomonocytic, Acute / Q000276:immunology / Q000628:therapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D014184:Transplantation, Homologous; D014185:Transplantation, Isogeneic
chemical_list: D007376:Interleukin-2